Skip to content
Clinical Trials – home
Universitaetsklinikum Erlangen AöR
Sponsor

Universitaetsklinikum Erlangen AöR

Germany Maximiliansplatz 2, Innenstadt, 91054 Erlangen, Germany

About the sponsor

Clinical research at Universitaetsklinikum Erlangen AöR includes systemic lupus erythematosus, systemic sclerosis, idiopathic inflammatory myositis, and progressive systemic autoimmune disease resistant to B cell depletion. Additional work covers psoriatic arthritis, axial spondyloarthritis, and early rheumatoid arthritis.

  • CAR-T cell therapy for refractory autoimmune disease
  • JAK inhibition in inflammatory joint disease
  • Interleukin-targeted therapy in psoriatic arthritis
  • Immunosuppressive tapering in stable disease control

The sponsor also studies enthesitis and pain processing in inflammatory arthritis, with interest in treatment-resistant immune-mediated conditions.

About Specializations

Universitaetsklinikum Erlangen AöR runs clinical trials in conditions such as Psoriatic arthropathy, Chronic kidney disease, Systemic scleroderma, Systemic lupus erythematosus, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Condition
Country
City
Type of trial
Recruitment status
Quick filters

13 clinical trials

Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:SP16
  • Sponsor:Universitaetsklinikum Erlangen AöR
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Idecabtagene Vicleucel
  • Sponsor:Universitaetsklinikum Erlangen AöR
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Aldesleukin
  • Sponsor:Universitaetsklinikum Erlangen AöR
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Dapagliflozin
  • Sponsor:Universitaetsklinikum Erlangen AöR
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Oxygen
  • Sponsor:Universitaetsklinikum Erlangen AöR
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Guselkumab
  • Sponsor:Universitaetsklinikum Erlangen AöR
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Abatacept
  • Sponsor:Universitaetsklinikum Erlangen AöR

Colitis ulcerative

Not yet recruiting
Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:AUTOLOGOUS REGULATORY T-CELLS WITH AN IMMUNOPHENOTYPE OF CD4+CD25HI/+FOXP3+
  • Sponsor:Universitaetsklinikum Erlangen AöR
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Dacarbazine
  • Sponsor:Universitaetsklinikum Erlangen AöR
Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ixekizumab
  • Sponsor:Universitaetsklinikum Erlangen AöR

Psoriatic arthropathy

Not recruiting
Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Upadacitinib
  • Sponsor:Universitaetsklinikum Erlangen AöR

Rheumatoid arthritis

Not recruiting
Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Baricitinib
  • Sponsor:Universitaetsklinikum Erlangen AöR

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).